The Efficacy and Safety of Anlotinib in Pediatric Patients With Refractory or Recurrent Solid Tumors

Overview of attention for article published in Frontiers in Pharmacology, March 2022

Altmetric Badge

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 2 Dimensions

Readers on

mendeley: 4 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 1 X post from an account with 5,739 followers.

New Research: The Efficacy and Safety of Anlotinib in Pediatric Patients With Refractory or Recurrent Solid Tumors https://t.co/0wSck7GJID #pharmacology

31 Mar 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.